Mast Therapeutics (MSTX) Reports In-Line Q4 Loss

Mast Therapeutics (NYSE: MSTX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Occidental Petroleum releases Q2 2026 earnings considerations
• Apollo agrees to buy EasyJet Plc. (EZJ:LN) (ESYJY); Bernstein SocGen shares investment implications